Reversing the effects of Alzheimer's Disease: Dr. Ron Geyer on NeuroEPO
Release Date: 02/19/2023
Dr. Sabira Valiani: Creating Connections in Critical Care
Researchers Under the Scope
Dr. Sabira Valiani was one of the frontline physicians working inside Saskatoon’s critical care units four years ago, during the initial lockdowns of the Covid-19 pandemic. “It was really weird,” said Valiani. Valiani said ‘a lot of light bulbs went off in my head’ amid the automated stillness of the unit, as she watched ventilators breathing for heavily sedated patients. Covered in head-to-toe personal protective equipment, staff in the intensive care unit struggled to simultaneously treat patients, communicate with family members, and enforce hospital...
info_outline
Dr. Daphne Yau on Blood Sugar & Brain Health
Researchers Under the Scope
Daphne Yau can trace her interest in endocrinology back to a beta-cell physiology experiment during her master’s degree, working with laboratory mice with Type 2 Diabetes. “It was the part of the pancreas that makes insulin,” she said. “It was fascinating. It also made me realize that maybe pure laboratory research wasn't quite for me." From there, her interest in hormones and fluctuating blood sugar levels grew. Yau is no stranger to medicine. Her mother was a pharmacist, while her father and aunt both worked as physicians. Following in their footsteps, Lou completed her...
info_outline
Dr. Sam Haddad: At the Heart of Patient Care
Researchers Under the Scope
Haissam Haddad inadvertently horrified his family when he signed up for engineering courses in his first year of university. The teenager returned the next day to change his major to medicine -- a move he's glad he made. Dr. Haddad practiced family medicine in Syria for three years, then arrived in Canada in 1986 to visit his wife's family, who urged him to stay. Haddad faced an uphill battle when he investigated the possibility of becoming a Canadian doctor. One colleague even told him he’d be better off opening a Syrian grocery store. “This gave me a lot of energy to prove him wrong,”...
info_outline
Remote Rehabilitation: Dr. Stacey Lovo's Quest for Equitable Care
Researchers Under the Scope
In this episode, we meet Dr. Stacey Love, Director of Virtual Physiotherapy and Rehabilitation at Saskatchewan's Virtual Health Hub, and an Assistant Professor at the University of Saskatchewan's School of Rehabilitation. She's also involved with the Saskatchewan Centre for Patient Oriented Research. You can see more of her recent publications , along with links to her labs: Musculoskeletal Health and Access to Care: Virtual Care and Remote Presence: Stacey Lovo remembers the bitterly cold day in December 2012, when two Indigenous women from northern Saskatchewan stepped off the...
info_outline
Dr. Angelica Lang: Shaping the Future of Shoulder Health
Researchers Under the Scope
knows most of the people she sees have to keep working, even if they have shoulder pain. As an and director of the Musculoskeletal and Ergonomics Lab at the Canadian Centre for Rural and Agricultural Health, Lang’s goal is to reduce that pain — keeping patients on the job. “A lot of daily life has to be done with your hands,” she said. “The base of that is your shoulder. It allows you to position your hand in all these different ways.” Lang knows the importance of movement. She grew up in Melfort, Sask., playing hockey, soccer, volleyball, along with track...
info_outline
Stronger Foundations: Dr. Munier Nour on Bone Development in Diabetic Youth
Researchers Under the Scope
Dr. Munier Nour said osteoporosis is often seen as a disease that affects older adults. But compared to their peers, kids with Type 1 diabetes grow into adults eight times as likely to suffer bone fractures. “Osteoporosis may actually have its origins during pediatric years,” he said. “Because Type 1 diabetes occurs so early in life ….. it influences that bone development that occurs during your peak growth.” Now, Nour is a co-lead on a national team trying to figure out why. The pediatric endocrinologist has always taken a logical approach to problem-solving....
info_outline
Thriving Against The Odds: Dr. Amanda Hall on Short Gut Syndrome
Researchers Under the Scope
In the heart of the Health Sciences Building, studies a tray of organoids under a microscope. “They do need a lot of attention and a lot of feeding,” she said, pointing to dot-like points in a gel solution. The pediatric surgeon and assistant professor of pediatric general surgery will use those dots to identify factors that help infants overcome short gut syndrome. The rare condition affects roughly 24 in every 100,000 babies born in Canada, presenting a profound challenge for infants born with insufficient intestinal length or compromised absorptive capacity. “It’s a...
info_outline
Inhale, Exhale, Repair: Dr. Valerie Verge
Researchers Under the Scope
Valerie Verge was in her early twenties when she landed her first job, doing neuroscience research and she loved it. But 43 years ago, her research journey began to take a twist. "I developed an allergy to rats and mice,” she said. “I was using a box of Kleenex a day.” She reluctantly had to admit that this may not be her career path, and spent her evenings earning a ‘back-up plan’ degree in computer programming at McGill. She refused to give up laboratory work, and went on with her colleagues to code and create an in house computerized image analysis system that was not...
info_outline
Fighting Treatment-Resistant Depression with Ketamine: Dr. Evyn Peters
Researchers Under the Scope
Dr. Evyn Peters has created pivotal changes for patients arriving at Royal University Hospital's mental health short stay unit, and its emergency department. With 33 publications and interests spanning , Peters is often one of the first physicians patients see when they’re experiencing a mental health crisis. Peters was finishing his residency at RUH and the University of Saskatchewan’s College of Medicine in 2017, when he and his colleagues first proposed ketamine for short-stay patients who had tried multiple antidepressants without success. After studying best practices in...
info_outline
Dr. Wendie Marks: Researching Complex Connections Between Stress, Nutrition & Health
Researchers Under the Scope
By the end of her Grade Eight year in Saskatoon, Wendie Marks was sure about one thing: she knew she wanted to study health and the way early-life development affected the human body. “I spent a lot of time in the library reading books,” Marks said. “I was always kind of the nerdy type.” Marks enrolled at the University of Saskatchewan and thrived, earning her PhD in psychology. Her interests evolved towards behavioural neuroscience, focusing on the mechanisms behind behaviour, stress, and their effects on mental and physical health. “I wanted to make new...
info_outlineFor decades, families have watched Alzheimer's disease steal their loved ones' cognitive function. It's the most common form of dementia; one that affects a third of people over the age of 85.
It's a disease Dr. Ron Geyer and Dr. Andrew Kirk want to tackle.
Right now, most pharmaceuticals target the symptoms of Alzheimer's disease, without addressing its root cause. Most lose their effectiveness after three months.
Geyer, a biochemist and professor of pathology at the University of Saskatchewan's College of Medicine, said a novel protein could change that.
"They did a first clinical trial with this drug and they showed pretty exceptional efficacy," said Geyer.
NeuroEPO, first developed by researchers at the Center for Molecular Immunology in Cuba, stimulates red blood cells in the brain. It's a recombinant form of the naturally produced erythropoietin protein (EPO), which stops neuron cells from dying, promoting their growth and communication mechanisms.
During its first round of human trials in early-stage Alzheimer's disease patients, 82 per cent of those receiving the treatment saw stabilization in their cognitive function. For more than half receiving the drug, cognitive function improved.
Alzheimer's disease progressed and worsened for almost everyone receiving the placebo.
"We decided to move this forward and do a Phase Two trial in Canada," Geyer said.
Once the study is approved by Health Canada, trials will involve between 80 and 100 patients. Geyer said so far, everything is on track to begin testing NeuroEPO this summer.
The trick, he said, is delivering the drug directly to the brain.
"It breaks down in the blood quicker than normal EPO, so that's good in that it doesn't cause side effects," Geyer said.
He said his research group has teamed up with Rocket Science Health Inc., a company that's developed a way to deliver NeuroEPO through the nose to the brain.
Compared to a Covid-19 nasal swab, Geyer said the delivery mechanism for this drug is 'much more comfortable'.
Working with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Geyer said his team is also expanding PET scans and neurological diagnostic tools for patients taking part in the study.
"We're hoping that with that, with those diagnostic assays, including MRI to measure the total brain volume, that the clinicians can use this information immediately as the trial starts to better diagnose their Alzheimer's patients, provide more clarity on the diagnosis, let them develop a treatment plan earlier."
Geyer said patients and doctors in Saskatchewan have already contacted his team, trying to sign up.
"We want to make it as broadly available as possible," he said.
Still, NeuroEPO will not be widely available, until a third-phase trial in the future which proves the drug's efficacy, shows no adverse effects, and involves at least 300-500 patients with Alzheimer's disease.
Geyer said his team is up to the challenge.
"It's almost impossible to find someone who doesn't know someone who has some form of dementia," said Geyer. "The ultimate goal is to keep people out of the hospital."